The immunomodulatory effect of inhaled granulocyte-macrophage colony-stimulating factor in cystic fibrosis. A new treatment paradigm

Lars Heslet, Christiane Bay, Steen Nepper-Christensen

8 Citationer (Scopus)

Abstract

Patients with cystic fibrosis (CF) experience recurrent infections and develop chronically infected lungs, which initiates an altered immunological alveolar environment. End-stage pulmonary dysfunction is a result of a long sequence of complex events in CF, progressing to alveolar macrophage dysfunction via a T-helper 2 (T(H)2) dominated alveolar inflammation with CD20 T-cell activation, induced by the chronic infection and showing a poor prognosis. There is great potential for treatment in transforming the T(H)2 into the more favorable T-helper 1 (T(H)1) response.
OriginalsprogEngelsk
TidsskriftJournal of Inflammation Research
Vol/bind5
Sider (fra-til)19-27
Antal sider9
ISSN1178-7031
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'The immunomodulatory effect of inhaled granulocyte-macrophage colony-stimulating factor in cystic fibrosis. A new treatment paradigm'. Sammen danner de et unikt fingeraftryk.

Citationsformater